CD19 and chronic asthma: We next investigated whether the protection afforded by the prophylactic ES1 and therapeutic ES3 (post-onset of lung pathology associated with chronic asthma) interventions also reflected resetting of IL-10+Bregs levels: analysis at d69 cull suggested that prophylactic treatment with ES-62 (ES1) did not modulate the levels of either MZ- or MZP-like Bregs (Fig. 6a) and indeed, if anything each of the ES1 and ES3, but not the ES2, treatments appeared to decrease the levels of CD19+IL-10+ (Bregs) and CD19−IL-10+ lymphocytes (Fig. 6b,c) in the spleen at this time.